Study: Moderna, Merck vaccines could cut melanoma's recurrence by 44 percent
There could be light at the end of the tunnel for individuals battling melanoma cancer. CBS News reported that researchers conducted a study to develop a "potential skin cancer vaccine" from Merck and Moderna, and found some promising results.
According to Reuters, a combination of Moderna's experimental melanoma vaccine and Merck's immunotherapy Keytruda "cut the risk of skin cancer's recurrence or death by 44 percent compared with Keytruda alone in a mid-stage trial."
Moderna's trial shot uses the same mRNA vaccine technology that has played an integral role in the success of COVID-19 vaccines, and the combination with Keytruda "has the capacity to be a new paradigm in the treatment of cancer," Paul Burton, Moderna's chief medical officer said in an interview.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
There were 157 melanoma patients involved in the ongoing clinical trial, and researchers noted side effects in 14.4 percent of the patients who received the drug-vaccine combo compared to 10 percent of people who were only administered Keytruda, writes Reuters.
CBS notes that the shares of both the pharmaceutical and biotech companies increased on Tuesday after researchers reported a positive outcome of the shots midway through the study.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Kelsee Majette has worked as a social media editor at The Week since 2022. In 2019, she got her start in local television as a digital producer and fill-in weather reporter at NTV News. Kelsee also co-produced a lifestyle talk show while working in Nebraska and later transitioned to 13News Now as a digital content producer.
-
‘These moves would usher in a future of chemical leaks’Instant Opinion Opinion, comment and editorials of the day
-
Trump unveils $12B bailout for tariff-hit farmersSpeed Read The president continues to insist that his tariff policy is working
-
Paramount fights Netflix for Warner as Trump hoversSpeed Read Paramount Skydance is seeking to undo Netflix’s purchase of Warner Bros. Discovery
-
5 recent breakthroughs in biologyIn depth From ancient bacteria, to modern cures, to future research
-
Blue Origin launches Mars probes in NASA debutSpeed Read The New Glenn rocket is carrying small twin spacecraft toward Mars as part of NASA’s Escapade mission
-
Dinosaurs were thriving before asteroid, study findsSpeed Read The dinosaurs would not have gone extinct if not for the asteroid
-
SpaceX breaks Starship losing streak in 10th testspeed read The Starship rocket's test flight was largely successful, deploying eight dummy satellites during its hour in space
-
Rabbits with 'horns' sighted across Coloradospeed read These creatures are infected with the 'mostly harmless' Shope papilloma virus
-
Lithium shows promise in Alzheimer's studySpeed Read Potential new treatments could use small amounts of the common metal
-
Scientists discover cause of massive sea star die-offSpeed Read A bacteria related to cholera has been found responsible for the deaths of more than 5 billion sea stars
-
'Thriving' ecosystem found 30,000 feet underseaSpeed Read Researchers discovered communities of creatures living in frigid, pitch-black waters under high pressure
